Table 1.
Demographic data, comorbidities and travel history of 19 SARS-CoV-2-infected patients with or without olfactory dysfunction.
| Total (n = 19) | 0lfactory dysfunction (n = 13) | No olfactory dysfunction (n = 6) | P value | |
|---|---|---|---|---|
| Age, median (IQR), y | 28.0 (24.0–48.0) | 26.0 (22.5–35.5) | 43.0 (32.5–60.3) | 0.012 |
| Male, No. (%) | 12 (63.2) | 9 (69.2) | 3 (50.0) | 0.617 |
| Comorbiditiesa, No. (%) | 3 (15.8) | 1 (7.7) | 2 (33.3) | 0.222 |
| Travel to other country | 16 (84.2) | 12 (92.3) | 4 (66.7) | 0.222 |
| Europe | 6 (31.6) | 5 (38.5) | 1 (16.7) | |
| United States | 5 (26.3) | 3 (23.1) | 2 (33.3) | |
| Asia | 4 (21.1) | 3 (23.1) | 1 (16.7) | |
| Warship to Palau | 1 (5.3) | 1 (7.7) | 0 (0) |
a
Comorbidities are including diabetes, heart disease and hepatitis in the patient without olfactory dysfunction patient and allergic rhinitis in the patient with olfactory dysfunction; there were no comorbidities of hypertension, airway disease, sinusitis, autoimmunity disease, or malignancy.